Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Debra Patt, MD, PhD, MBA, executive vice president of policy and strategic initiatives and director of public policy at Texas Oncology, joins hosts Emeline Aviki, MB, MBA, medical director and attending surgeon at NYU Langone Perlmutter Cancer Center, and Stephen, MD, MBA, chief medical officer at Tennessee Oncology, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Patt is a policy and physician expert, breast cancer specialist, and board member of the Community Oncology Alliance and American Society of Clinical Oncology. Her in-depth conversation with Aviki and Schleicher addresses several important issues currently affecting high-quality oncology care: most important, the current drug shortage, and the economics that made it a problem, innovative ways to fix it, and economic solutions to prevent it from perpetuating.
They also discuss the instability of drug pricing—wholesale acquisition cost vs average sales price—the relationship between cancer and aging, pharmacy benefits managers and how they have affected the price of cancer care, and facilitating meaningful change for patients.
For audio only:
Listen above or on one of these podcast services:
Learning From Past Innovations to Advance Ventilation Use in Respiratory Conditions
May 21st 2024In a keynote presentation at ATS 2024, Hannah Wunsch, MD, MSc, of Weill Cornell Medicine, delved into how the history of breathing support dating back to the 1700s has set the stage for ventilation advances still being made today.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More